Patents by Inventor Ronald Borchardt

Ronald Borchardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080090785
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: May 9, 2005
    Publication date: April 17, 2008
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, Kevin Shenk, Peggy Radel
  • Publication number: 20070191284
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: April 11, 2007
    Publication date: August 16, 2007
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser
  • Publication number: 20070176071
    Abstract: The present invention is directed to a novel packaging clip for retaining a plurality of containers. The clip comprises a rectangular frame made of a resilient material and having length and width dimensions. The rectangular frame has a plurality of circular apertures having open mouths and two arms adjacent to and forming the open mouths. The number of arms is one more than the number of circular apertures. The circular apertures have inner diameters that are substantially equivalent to the diameters of the containers to be retained by the clip. The open mouths of the circular apertures are positioned along the length dimension of the frame so that the mouths open in only one direction. Additionally, the open mouths of the circular apertures are smaller than the inner diameter of the circular apertures and smaller than the diameter of the containers to be retained by the clip.
    Type: Application
    Filed: January 30, 2006
    Publication date: August 2, 2007
    Inventors: Ronald Borchardt, Jeffrey Minnette, Clayton Robinson, Randall Julian
  • Publication number: 20060281722
    Abstract: The invention features charge-modified antidepressants and compounds conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a compound of the invention.
    Type: Application
    Filed: February 13, 2006
    Publication date: December 14, 2006
    Inventors: Michael Foley, Curtis Keith, Ronald Borchardt
  • Publication number: 20050245435
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: April 14, 2005
    Publication date: November 3, 2005
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, John Schneekloth, John Chabala